| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA757: Cabotegravir and rilpivirine for treating HIV-1 |
|
Medicine details |
|
| Medicine name | cabotegravir (Vocabria®) |
| Formulation | 400 mg/ 2 ml prolonged-release suspension for injection, 600 mg/ 3 ml prolonged-release suspension for injection; 30 mg film-coated tablet |
| Reference number | 2977 |
| Indication | In combination with rilpivirine injection, for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the NNRTI and INI class |
| Company | ViiV Healthcare UK Ltd |
| BNF chapter | Infections |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 12/11/2020 |
| NICE guidance | |